Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked hard but unsuccessfully to create an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the treatment of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the past several shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What To Do When It’s Too Good In order to Be True?”, set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely marketing image in the Uptick Newswire interview that I came away with a bad viewpoint of the company.

Irony of irony, my bad viewpoint of the company has grown steadily, although the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the expertise as well as linked intellectual property coming from Progenics to CytoDyn, as well as approximately 25 million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) and also the very first brand new drug program approval ($five million), and also royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to get a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and multiple therapies, it’s this individual therapies as well as a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple illness sorts, multiple publications and multiple presentations.

Might all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself with the really beginning of the interest of mine in this company. Judging by way of the multiples of a huge number of various commentary on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am much from alone in this particular question.

CytoDyn is a classic battleground, or even some might say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *